Covaxin booster dose increases immune response by 40 times: Bharat Biotech - Video

Published On 2022-07-21T18:00:00+05:30 | Updated On 21 July 2022 6:00 PM IST

Overview

Bharat Biotech International Limited (BBIL), has announced that BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine, has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. The study has been accepted and published in Nature Scientific Reports, a high impact factor journal.

The study was conducted in ~184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, ~6 months after the primary series of 2 doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, N proteins, and for memory T and B cell responses to demonstrate cell mediated immunity.

For more details, check out the full story on the link below:

Bharat Biotech Says Covaxin Booster Dose Increases Immune Response By 40 Times

Speakers

Rahul Verma

Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751